Oramed Pharmaceuticals Stock Today
| ORMP Stock | USD 2.44 0.02 0.81% |
Performance0 of 100
| Odds Of DistressLess than 8
|
Oramed Pharmaceuticals is selling at 2.44 as of the 30th of April 2024; that is -0.81 percent down since the beginning of the trading day. The stock's last reported lowest price was 2.36. Oramed Pharmaceuticals has only a 8 % chance of going through financial distress over the next few years, but has generated negative returns over the last 90 days. Equity ratings for Oramed Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 6th of May 2023 and ending today, the 30th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 21st of April 2006 | Category Healthcare | Classification Health Care |
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York. The company has 40.52 M outstanding shares of which 367.6 K shares are now shorted by private and institutional investors with about 3.11 trading days to cover. More on Oramed Pharmaceuticals
Moving against Oramed Stock
| 0.59 | MMM | 3M Company Financial Report 23rd of July 2024 | PairCorr |
| 0.57 | CGC | Canopy Growth Corp Downward Rally | PairCorr |
| 0.42 | GE | GE Aerospace Earnings Call This Week | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 9th of May 2024
Oramed Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Oramed Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Oramed Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO President | Nadav Esq | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Tel Aviv 60, NASDAQ Composite, NASDAQ Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Oramed Pharmaceuticals report their recommendations after researching Oramed Pharmaceuticals' financial statements, talking to executives and customers, or listening in on Oramed Pharmaceuticals' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Oramed Pharmaceuticals. The Oramed consensus assessment is calculated by taking the average forecast from all of the analysts covering Oramed Pharmaceuticals. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Oramed Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Oramed Pharmaceuticals is not in a good financial situation at this time. It has a very high probability of going through financial hardship in May. Financial strength of Oramed Pharmaceuticals is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Oramed Pharmaceuticals' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Oramed Pharmaceuticals' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Oramed Pharmaceuticals' financial leverage. It provides some insight into what part of Oramed Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Oramed Pharmaceuticals (ORMP) is traded on NASDAQ Exchange in USA. It is located in 1185 Avenue of the Americas, New York, NY, United States, 10036 and employs 25 people. Oramed Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 99.68 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Oramed Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Oramed Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Oramed Pharmaceuticals conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 40.52 M outstanding shares of which 367.6 K shares are now shorted by private and institutional investors with about 3.11 trading days to cover.
Oramed Pharmaceuticals currently holds about 133.91 M in cash with (27.92 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.45, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Oramed Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationOramed Pharmaceuticals has a total of 40.52 Million outstanding shares. Oramed Pharmaceuticals holds 11.3 pct. of its outstanding shares held by insiders and 12.88 pct. owned by third-party entities. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Oramed Ownership Details
Oramed Stock Price Odds Analysis
In regard to a normal probability distribution, the odds of Oramed Pharmaceuticals jumping above the current price in 90 days from now is about 86.81%. The Oramed Pharmaceuticals probability density function shows the probability of Oramed Pharmaceuticals stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.8748. This indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Oramed Pharmaceuticals will likely underperform. Additionally, oramed Pharmaceuticals has an alpha of 0.0726, implying that it can generate a 0.0726 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of Oramed Pharmaceuticals to move above the current price in 90 days from now is about 86.81 (This Oramed Pharmaceuticals probability density function shows the probability of Oramed Stock to fall within a particular range of prices over 90 days) .
Oramed Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Oramed Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Oramed Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Oramed Pharmaceuticals' value.| Instituion | Recorded On | Shares | |
| Qube Research & Technologies | 2023-12-31 | 86.5 K | |
| Morgan Stanley - Brokerage Accounts | 2023-12-31 | 64.2 K | |
| State Street Corporation | 2023-12-31 | 58 K | |
| Susquehanna International Group, Llp | 2023-12-31 | 45.9 K | |
| Lpl Financial Corp | 2023-12-31 | 43.2 K | |
| Jpmorgan Chase & Co | 2023-12-31 | 28.8 K | |
| Pnc Financial Services Group Inc | 2023-12-31 | 26.2 K | |
| Geode Capital Management, Llc | 2023-12-31 | 25.5 K | |
| American Century Companies Inc | 2023-12-31 | 19.3 K | |
| Murchinson Ltd. | 2023-12-31 | 1.1 M | |
| Bml Capital Management Llc | 2024-03-31 | 844.5 K |
Oramed Pharmaceuticals Historical Income Statement
Oramed Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting Oramed's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Oramed Pharmaceuticals revenue and expense. Oramed Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Oramed Pharmaceuticals' Gross Profit is relatively stable compared to the past year. As of 04/30/2024, Net Interest Income is likely to grow to about 5.6 M, though EBIT is likely to grow to (34.7 M). View More FundamentalsOramed Stock Against Markets
Picking the right benchmark for Oramed Pharmaceuticals stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Oramed Pharmaceuticals stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Oramed Pharmaceuticals is critical whether you are bullish or bearish towards Oramed Pharmaceuticals at a given time. Please also check how Oramed Pharmaceuticals' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Oramed Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run USA ETFs Now
USA ETFsFind actively traded Exchange Traded Funds (ETF) in USA |
| All Next | Launch Module |
Oramed Pharmaceuticals Corporate Directors
Oramed Pharmaceuticals corporate directors refer to members of an Oramed Pharmaceuticals board of directors. The board of directors generally takes responsibility for the Oramed Pharmaceuticals' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Oramed Pharmaceuticals' board members must vote for the resolution. The Oramed Pharmaceuticals board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Roy Eldor | Director | Profile | |
| Avram Hershko | Director | Profile | |
| Ele Ferrannini | Director | Profile | |
| Miriam Kidron | Chief Scientific Officer and Director | Profile |
How to buy Oramed Stock?
Before investing in Oramed Pharmaceuticals, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Oramed Pharmaceuticals. To buy Oramed Pharmaceuticals stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Oramed Pharmaceuticals. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Oramed Pharmaceuticals stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Oramed Pharmaceuticals stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Oramed Pharmaceuticals stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Oramed Pharmaceuticals, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Oramed Stock please use our How to Invest in Oramed Pharmaceuticals guide.
Already Invested in Oramed Pharmaceuticals?
The danger of trading Oramed Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Oramed Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Oramed Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Oramed Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Oramed Pharmaceuticals is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Oramed Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Oramed Pharmaceuticals Stock. Highlighted below are key reports to facilitate an investment decision about Oramed Pharmaceuticals Stock: Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oramed Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. To learn how to invest in Oramed Stock, please use our How to Invest in Oramed Pharmaceuticals guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Complementary Tools for Oramed Stock analysis
When running Oramed Pharmaceuticals' price analysis, check to measure Oramed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oramed Pharmaceuticals is operating at the current time. Most of Oramed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Oramed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oramed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Oramed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |
Is Oramed Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oramed Pharmaceuticals. If investors know Oramed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oramed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.14 | Revenue Per Share 0.033 | Quarterly Revenue Growth (1.00) | Return On Assets (0.05) | Return On Equity 0.0324 |
The market value of Oramed Pharmaceuticals is measured differently than its book value, which is the value of Oramed that is recorded on the company's balance sheet. Investors also form their own opinion of Oramed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Oramed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oramed Pharmaceuticals' market value can be influenced by many factors that don't directly affect Oramed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oramed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oramed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oramed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.